company background image
ADPT logo

Adaptive Biotechnologies NasdaqGS:ADPT Stock Report

Last Price

US$3.21

Market Cap

US$419.3m

7D

-3.6%

1Y

-61.9%

Updated

28 Mar, 2024

Data

Company Financials +

Adaptive Biotechnologies Corporation

NasdaqGS:ADPT Stock Report

Market Cap: US$419.3m

ADPT Stock Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.

ADPT fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Adaptive Biotechnologies Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Adaptive Biotechnologies
Historical stock prices
Current Share PriceUS$3.21
52 Week HighUS$9.08
52 Week LowUS$2.61
Beta1.27
1 Month Change-24.82%
3 Month Change-34.49%
1 Year Change-61.88%
3 Year Change-92.13%
5 Year Changen/a
Change since IPO-92.03%

Recent News & Updates

Adaptive Biotechnologies: A Post Earnings Assessment

Feb 25

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Feb 17
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Recent updates

Adaptive Biotechnologies: A Post Earnings Assessment

Feb 25

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Feb 17
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Feb 01
Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Nov 17
Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Oct 13
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Jul 06
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

May 05
Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Apr 15
We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Dec 13
Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system

Oct 11

Adaptive Biotechnologies announces $250M non-dilutive royalty financing

Sep 12

We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Aug 14
We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Apr 29
Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Adaptive Biotechnologies: Good Buy For Long-Term Investors

Apr 15

Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

Feb 26
Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth

Jan 09
We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth

Our First Assessment On Adaptive Biotechnologies

Dec 16

Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Sep 26
Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Situation

Jun 07
Here's Why We're Not Too Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Situation

Adaptive Biotechnologies: Stock Isn't Cheap

Jun 04

Shareholder Returns

ADPTUS Life SciencesUS Market
7D-3.6%-0.2%0.4%
1Y-61.9%4.5%28.8%

Return vs Industry: ADPT underperformed the US Life Sciences industry which returned 4.5% over the past year.

Return vs Market: ADPT underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is ADPT's price volatile compared to industry and market?
ADPT volatility
ADPT Average Weekly Movement9.6%
Life Sciences Industry Average Movement7.3%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ADPT's share price has been volatile over the past 3 months.

Volatility Over Time: ADPT's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009709Chad Robinshttps://www.adaptivebiotech.com

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD).

Adaptive Biotechnologies Corporation Fundamentals Summary

How do Adaptive Biotechnologies's earnings and revenue compare to its market cap?
ADPT fundamental statistics
Market capUS$419.32m
Earnings (TTM)-US$225.25m
Revenue (TTM)US$170.28m

2.7x

P/S Ratio

-2.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ADPT income statement (TTM)
RevenueUS$170.28m
Cost of RevenueUS$96.02m
Gross ProfitUS$74.26m
Other ExpensesUS$299.51m
Earnings-US$225.25m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.55
Gross Margin43.61%
Net Profit Margin-132.29%
Debt/Equity Ratio42.4%

How did ADPT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.